European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 645

Inclusion Criteria

BMI > 27 kg/m² and < 40 kg/m²,
Waist Circumference > 88 cm in women; > 102 cm in men,
HDL cholesterol < 40 mg/dL (1.03 mmol/L) for men; < 50 mg/dL (1.29 mmol/L) for women, and/or Triglycerides ≥ 150 mg/dL (1.69 mmol/L),
LDL cholesterol up to 155 mg/dl (4.00 mmol/L) including patients on a stable dose of statins and/or Ezetimibe therapy for at least 8 weeks prior to screening

Concomitant medications:

Current treatment with statins and/or ezetimibe and/or antihypertensive therapy must be at fixed and stable dose for at least 8 weeks prior to screening visit,
Patients, who are willing and in the opinion of the Investigator safely assumed to remain on stable and fixed doses of antihypertensive, and/or statins and/or ezetimibe without adding additional medications or changing current treatment for the duration of the trial.

Exclusion Criteria

Pregnant or breast-feeding women, or women planning to become pregnant or breastfeed (excluded by pregnancy test),
Absence of medically approved contraceptive methods for female of childbearing potential,
History of very low-calorie diet within 3 months prior to screening visit (lower than 1200 Kcal/day),
Weight change > 5 kg within 3 months prior to screening visit,
History of surgical procedures for weight loss (e.g., stomach stapling, bypass),
History of bulimia or anorexia nervosa as per DSM-IV criteria
Presence of any clinically significant endocrine disease according to the investigator, in particular known abnormal TSH and free T4 blood level (Patients treated with thyroid replacement therapy must be on fixed and stable dose for at least 3 months prior to screening and must be in euthyroïd status),
Established type 1 or 2 diabetes treated, or with at least 2 measures of fasting blood glucose ≥ 126 mg/dl,
Triglyceride level > 400 mg/dL (4.52 mmol/L),
Systolic blood pressure > 160 mm Hg or diastolic blood pressure >100 mmHg at screening visit,
Known severe renal dysfunction (creatinine clearance < 30 ml/min) or nephrotic syndrome or urinalysis (performed at screening by dipstick) showing 2+ or more protein,
Known severe hepatic impairment or AST and/or ALT > 3 times the upper limit of normal at screening,
Presence of any condition (medical, including clinically significant abnormal laboratory tests, psychological, social or geographical) actual or anticipated that the investigator feels would compromise the patient's safety or limit his/her successful participation to the study. In particular :
- Cardiac abnormalities: cardiac failure status NYHA III or IV, relevant acute abnormal finding seen on ECG at screening or within 6 months before screening,
- Any current malignancy or any cancer within the past five years (except adequately treated basal cell skin cancer or cervix carcinoma in situ),
- Significant haematology abnormalities (haemoglobin < 100 g/L and/or neutrophils < 1.5 G/L and/or platelets < 100 G/L),
- Acute psychiatric disorders, or mental condition which could interfere with the patient's compliance or safe participation in the study,
- Patient treated for epilepsy
Ongoing major depressive illness,
Uncontrolled psychiatric illness,
History of alcohol or other substance abuse,
Hypersensitivity /intolerance to the active substance or to any of the excipients such as lactose,

Concomitant medications prior to study entry::

Administration of any investigational treatment (drug or device) within 30 days prior to screening,
Previous participation in a Rimonabant study or previous administration of Rimonabant,
Administration of any of the following within 3 months prior to screening visit:
- anti obesity drugs (eg, sibutramine, orlistat),
- other drugs for weight reduction (phentermine, amphetamines),
- herbal preparations for weight reduction,
- nicotinic acid, fibrates or bile acid sequestrants,
- Prolonged use (more than one week) of systemic corticosteroids, neuroleptics,
- Omega-3 fatty acid approved medication
Ongoing antidepressive treatment (including bupropion)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	rimonabant	-
2	Placebo	-

Primary Outcome Measures

Name	Time	Method
Change in HDL-C and triglyceride levels	From baseline to end of treatment

Secondary Outcome Measures

Name	Time	Method
Waist circumference and body weight	At each visit
Glycemic parameters : FPG, fasting insulinemia, HbA1c,	Prior to baseline, month 3, month 6 and month 12.
Lipid parameters : Total Cholesterol, HDL-C, LDL-C, triglyceride levels	Prior to baseline, month 3, month 6 and month 12.
Inflammatory parameter : Hs-CRP	Prior to baseline, month 3, month 6 and month 12.
Quality of life : IWQOL questionnaire completed	At baseline, month 3, month 6, month 9 and month 12.
Incidence of adverse events in each group, including neuro-psychiatric adverse events	Prior to baseline, month 3, month 6 and month 12.
Standard laboratory assessments	Prior to baseline and month 12
In selected sites, a sub study will be conducted in which additional Lipid parameters will be measured: HDL subfractions, Apo A1, Apo A2, Apo B and Apo C3, Lp A1, LpA1/A2, Lp(a), Oxidized-LDL and LDL size	Prior to baseline and at month 12
In selected sites, a sub study will be conducted in which additional Inflammatory parameters will be measured: Adiponectin-High Molecular Weight, Intracellular adhesion molecule 1(ICAM-I) and TNFalpha.	Prior to baseline and at month 12

European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia

Recruitment & Eligibility

Study & Design

Trial Locations

Instant Trial Alerts

Instant Trial Alerts